ATE221048T1 - Fluorierte prostaglandinderivate und medikamente - Google Patents

Fluorierte prostaglandinderivate und medikamente

Info

Publication number
ATE221048T1
ATE221048T1 AT97940373T AT97940373T ATE221048T1 AT E221048 T1 ATE221048 T1 AT E221048T1 AT 97940373 T AT97940373 T AT 97940373T AT 97940373 T AT97940373 T AT 97940373T AT E221048 T1 ATE221048 T1 AT E221048T1
Authority
AT
Austria
Prior art keywords
group
medicine
hydrogen atoms
double bond
eye disease
Prior art date
Application number
AT97940373T
Other languages
English (en)
Inventor
Eiichi Shirasawa
Takayama-Cho
Masaaki Kageyama
Nobuaki Mori
Kanagawa-Ku Cho
Kazuhisa Sakata
Takashi Nakano
Yasushi Matsumura
Yoshitomi Morizawa
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27276117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE221048(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP8346286A external-priority patent/JPH10182598A/ja
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of ATE221048T1 publication Critical patent/ATE221048T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT97940373T 1996-09-17 1997-09-12 Fluorierte prostaglandinderivate und medikamente ATE221048T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP24515596 1996-09-17
JP8346286A JPH10182598A (ja) 1996-12-25 1996-12-25 含フッ素プロスタグランジン誘導体の製造方法
JP410997 1997-01-13
PCT/JP1997/003236 WO1998012175A1 (en) 1996-09-17 1997-09-12 Fluorinated prostaglandin derivatives and medicines

Publications (1)

Publication Number Publication Date
ATE221048T1 true ATE221048T1 (de) 2002-08-15

Family

ID=27276117

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940373T ATE221048T1 (de) 1996-09-17 1997-09-12 Fluorierte prostaglandinderivate und medikamente

Country Status (4)

Country Link
EP (1) EP0930296B2 (de)
AT (1) ATE221048T1 (de)
DE (1) DE69714274T3 (de)
WO (1) WO1998012175A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
DK1012137T3 (da) * 1997-09-09 2003-03-10 Procter & Gamble Aromatiske C-16-C-20-substituerede tetrahydro-prostaglandiner og deres anvendelse som prostaglandin FP-agonister
ES2253826T3 (es) * 1997-09-09 2006-06-01 Duke University Prostaglandinas aromaticas tetrahidro sustituidas por c16-c20 utilizadas como agonistas fp.
IL134839A0 (en) * 1997-09-09 2001-05-20 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
EP1321144B1 (de) * 2000-09-13 2010-12-08 Santen Pharmaceutical Co., Ltd. Augentropfen
US6476064B1 (en) * 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
SI1864666T1 (sl) 2005-03-31 2012-10-30 Asahi Glass Co Ltd Zaščitno sredstvo za retinalno nevronsko celico, vsebujoče derivat prostaglandina F2 alfa kot učinkovino
WO2006112313A1 (ja) 2005-04-13 2006-10-26 Ube Industries, Ltd. インダゾール誘導体を有効成分として含む網膜神経細胞保護剤
JP4851467B2 (ja) * 2006-02-07 2012-01-11 株式会社アールテック・ウエノ プロスタグランジン誘導体の製造法
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
EP2127638A1 (de) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
ES2834451T3 (es) 2009-05-01 2021-06-17 Aerie Pharmaceuticals Inc Inhibidores de mecanismo doble para el tratamiento de enfermedades
EP2976080B1 (de) 2013-03-15 2019-12-25 Aerie Pharmaceuticals, Inc. Konjugate von isoquinolinverbindungen und prostaglandinen
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2317964T5 (es) † 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH0770054A (ja) † 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
DE69705421T2 (de) † 1996-11-12 2002-05-16 Alcon Laboratories, Inc. 15-fluoro-prostaglandine als augendrucksenkende mittel
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
DK1012137T3 (da) * 1997-09-09 2003-03-10 Procter & Gamble Aromatiske C-16-C-20-substituerede tetrahydro-prostaglandiner og deres anvendelse som prostaglandin FP-agonister
US9259564B2 (en) † 2009-01-22 2016-02-16 Avent, Inc. Enteral feeding assembly with lock assembly

Also Published As

Publication number Publication date
DE69714274D1 (de) 2002-08-29
DE69714274T2 (de) 2003-03-27
EP0930296A4 (de) 1999-11-17
EP0930296A1 (de) 1999-07-21
EP0930296B1 (de) 2002-07-24
DE69714274T3 (de) 2006-06-01
EP0930296B2 (de) 2005-11-02
WO1998012175A1 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
ATE221048T1 (de) Fluorierte prostaglandinderivate und medikamente
NO2009006I2 (no) isopropyl(5Z)-7{(1R, 2R, 3R, 5S)-2-[(IE)-3,3-difluor-4-fenoksybut-l-enyl]-3,5-dihydroksycyklopentyl}hept-5-enoat eller 16-fenoksy-15-deoksy-15,15-difluor-17,18,19,20-tetranorprostaglandin F2a isopropyl ester
DK0644199T3 (da) Cykliske antimikrobielle peptider og fremstilling deraf
NZ238181A (en) N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions
KR960007545A (ko) 합성 흥분성 아미노산
EP1172107A4 (de) Heilmittel die sulfopyranosylacylglycerolderivate enthalten
DE69623497D1 (de) 1-methylcarbapenem-derivate
AU641686B2 (en) Benzanilides
DE69425970D1 (de) Benzol-derivate, verwendbar für ischämische erkrankungen
KR960703843A (ko) 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient)
DE69729890D1 (de) Heilmittel/vorbeugemittel für erkrankungen der atemwege
TH19860A (th) สารประกอบเอสเทอร์และสารควบคุมสิ่งมีชีวิตที่เป็นอันตราย ซึ่งมีสารประกอบเอสเทอร์นี้เป็นส่วนประกอบที่แสดงฤทธิ์

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties